Because of the intrinsic complexity, the classification of wounds is important for the diagnosis, management, and choosing the correct treatment based on wound type. Generally, burn injuries are classified as a class of wounds in which injury is caused by heat, cold, electricity, chemicals, friction, or radiation. On the other hand, wound healing is a complex process, and understanding the biological trend of this process and differences in the healing process of different wounds could reduce the possible risk in many cases and greatly reduce the future damage to the injured tissue and other organs. The aim of this review is to provide a general perspective for the burn wound location among the other types of injuries and summarizing as well as highlighting the differences of these types of wounds with emphasizing on factors affecting thereof.
30 December 2019 in Journal of Biomedical Materials Research Part B: Applied Biomaterials
Recently, wearing facemasks in public has been raised due to the coronavirus disease 2019 epidemic worldwide. However, the performance and effectiveness of many existing products have raised significant concerns among people and professionals. Therefore, greater attempts have been focused recently to increase the efficacy of these products scientifically and industrially. In this respect, doping or impregnating facemask fabrics with metallic substances or nanoparticles like silver nanoparticles has been proposed. So, in the present study, we aimed to sonochemically coat silver nanoparticles on the non-woven Spunbond substrates at different sonication times and concentrations to develop antibacterial and antiviral facemask. The coated substrates were characterized using Field Emission Scanning Electron Microscope, Energy Dispersive X-Ray, X-ray diffraction, and Thermogravimetry analysis. The amount of silver released from the coated substrates was measured by atomic absorption spectroscopy. The filtration efficiency, pressure drop, and electrical conductivity of the coated samples were also investigated. The antibacterial activity of fabrics was evaluated against Escherichia coli and Staphylococcus aureus. Cellular viability of samples assessed by MTT and brine shrimp lethality tests. The results revealed that the higher sonication times and precursor concentrations result in a higher and more stable coating, larger particle size, wider particle size distribution, and lower content of released silver. Coated fabrics also revealed enhanced filtration efficiency (against nanosize particles), desired pressure drop, and antibacterial activity without significant cytotoxicity toward HEK 293 cells and Artemia nauplii. As a result, the coated fabrics could find potential applications in the development of facemasks for protection against different pathogenic entities.
In the present study, 5-fluorouracil-loaded niosomal nanoparticles were successfully prepared and coated with chitosan and subsequently crosslinked by tripolyphosphate to form niosomal nanogels. The prepared niosomal formulations were fully characterized for their particle size, zeta potential, particle morphology, drug entrapment efficiency, and in vitro drug release profile. The prepared niosomal nanocarriers exhibited nanoscale particle sizes of 165.35 ± 2.75-322.85 ± 2.75 nm. Chitosan-coated and TPP-crosslinked niosomes exhibited a slightly decreased in particle size and a switch of zeta potential from negative to positive values. In addition, high yield percentage, drug encapsulation efficiency, and drug loading values of 92.11 ± 2.07 %, 66.59 ± 6.06, and 4.65 ± 0.5 were obtained for chitosan-coated formulations, respectively. Moreover, lowering the rate of 5-FU in vitro release was achieved within 72 h by using chitosan-coated formulations. All prepared formulations revealed hemocompatible properties in hemolysis assay with less than 5 % hemolysis percentage at their higher possible concentrations (500 µM and 1 mM). The cell viability by MTT assay showed higher anticancer activity against B16F10 cancerous cells and lower cytotoxicity toward NIH3T3 normal cells than control and pure 5-FU in the studied concentration range (10-100 µM). Investigating the cell migration inhibition properties of fabricated formulations revealed similar results with in vitro cell viability assay with a higher migration inhibition rate for B16F10 cells than NIH3T3 cells, controls, and free 5-FU.
Background: Women with breast cancer usually face multiple short-term and long-term problems in dealing with their acute and chronic symptoms during and after cancer treatment. However, serious gaps remain in addressing these issues in clinical and public health practice. Methods: According to the preferred reporting items for systematic reviews and meta-analyses (PRISMA) guidelines, we conducted a systematic literature search from 2000-2021 in electronic databases, including Medline, PubMed, Embase, Scopus, Web of Knowledge, and Google Scholar databases using predefined keywords. Results: The review identified several significant and interconnected problems in breast cancer patient’s treatment and supportive care. The results revealed that these issues are very common among breast cancer patients, and specific attention and serious measures are needed to address these problems. Despite implementing different protocols and programs for covering and addressing these problems, serious gaps still exist in supporting breast cancer patients during clinical and follow-up care. Conclusion: Developing innovative and holistic approaches and programs based on the multifactorial assessment of symptoms are suggested for addressing and covering the multidimensional requirements of this population. Consequently, thorough evaluation, education, treatment, and referrals should be provided for the most common sequelae of these patients by including appropriate medication, exercise, counselling, occupational therapy, and complementary therapies. The present study provides a more comprehensive source of information about breast cancer patient’s medical and supportive needs in comparison with individual studies on symptom experiences.
26 April 2022 in Journal of Drug Delivery Science and Technology